Gemini Therapeutics Inc
GMTX
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.
$1.68
-$0.05 (-2.89%)Jun 28
Vote for Gemini Therapeutics Inc Perks!
Looks like Gemini Therapeutics Inc doesn't offer shareholder perks yet... tell Gemini Therapeutics Inc (Tii:GMTX) you want perks by adding your email below.
Start earning perks today
Join NowHow it works
TiiCKER offers a completely personalized experience and first-ever way to view your stock portfolio, trade for free and invest in new companies while viewing your perks in one place!
Create a profile
Connect accounts
Discover brands
Collect rewards
About
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.
Start earning perks today
TiiCKER was created for fan-first, brand-first public companies—with exclusive perks served-up weekly to shareholders. Own stock? Connect your brokerage account to view more than 130 perks waiting for you right now!
